Bellon Christine 4
4 · Beam Therapeutics Inc. · Filed Jan 20, 2026
Insider Transaction Report
Form 4
Bellon Christine
Chief Legal Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-01-15$33.62/sh−2,111$70,976→ 113,556 total - Sale
Common Stock
[F1][F3]2026-01-15$34.72/sh−15,959$554,068→ 97,597 total - Sale
Common Stock
[F1][F4]2026-01-15$35.40/sh−559$19,788→ 97,038 total
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.17 to $34.15, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.355 to $35.34, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.38 to $35.485, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
By: /s/ Christine Bellon|2026-01-20